Ovid Therapeutics Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the results of the Annual Meeting of Stockholders held by Ovid Therapeutics Inc. on June 10, 2026. The report was filed on June 11, 2026. As of the record date of April 15, 2026, there were 173,037,131 shares of common stock outstanding.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Stockholder participation was 75.7% (130,958,928 shares present). The following proposals were voted upon:
- Proposal 1 (Election of Director): Jeremy M. Levin was elected to a three-year term. Votes: 87,219,707 For; 8,528,008 Withheld; 35,211,213 Broker Non-Votes.
- Proposal 2 (Advisory Executive Compensation): Approved. Votes: 84,511,953 For; 8,901,691 Against; 2,334,071 Abstain; 35,211,213 Broker Non-Votes.
- Proposal 3 (Ratification of Auditor): KPMG LLP was ratified for the fiscal year ending December 31, 2026. Votes: 130,845,667 For; 32,505 Against; 80,756 Abstain.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Jeremy M. Levin's director term extends until the 2029 annual meeting.
- KPMG LLP is confirmed as the independent auditor for the 2026 fiscal year.
- Broker non-votes totaled 35,211,213 shares for both the director election and executive compensation proposals.
- Refer to the definitive proxy statement filed on April 27, 2026, for detailed descriptions of the proposals.